Related Experiment Video

Updated: May 28, 2026

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

Recurrent ovarian cancer: when and how to treat

Marcia Hall1, Gordon Rustin

  • 1Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood, Middlesex, UK. marcia.hall@nhs.net

Current Oncology Reports
|November 3, 2011
PubMed

Insights

Recurrent ovarian cancer presents challenges, with early detection benefits questioned. Treatment choices, including surgery and novel agents like PARP inhibitors, require careful consideration and patient involvement.

Area of Science:

  • Gynecologic Oncology
  • Medical Oncology

Background:

  • Ovarian cancer frequently recurs despite primary treatment.
  • Current surveillance strategies and early intervention benefits are under scrutiny.

Purpose of the Study:

  • To explore treatment strategies for recurrent ovarian cancer.
  • To address the controversial timing of interventions for recurrent disease.
  • To emphasize patient education and shared decision-making.

Main Methods:

  • Review of current literature on recurrent ovarian cancer management.
  • Analysis of recent clinical trial data (e.g., MRC/EORTC CA125 trial).
  • Discussion of emerging therapies including antiangiogenic agents and PARP inhibitors.

Main Results:

  • The benefit of early detection and treatment of recurrence is uncertain.
  • Further investigation is needed on the survival impact of secondary cytoreductive surgery.
  • PARP inhibitors and antiangiogenic agents show increasing importance.

Conclusions:

  • Management of recurrent ovarian cancer involves complex choices regarding treatment and timing.
  • Patient education and involvement are crucial for optimal decision-making.
  • Further research is needed to clarify the role of secondary cytoreductive surgery.

More Related Videos

In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose13:04

In Vivo and Ex Vivo Approaches to Study Ovarian Cancer Metastatic Colonization of Milky Spot Structures in Peritoneal Adipose

Published on: October 14, 2015

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis10:58

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Disorders of the Female Reproductive System01:24

Disorders of the Female Reproductive System

The female reproductive system can be affected by several disorders, including Premenstrual Syndrome (PMS), Premenstrual Dysphoric Disorder (PMDD), endometriosis, and various forms of cancer. PMS and PMDD are cyclical conditions that cause physical and emotional distress, with symptoms that include edema, mood swings, and food cravings. PMDD is a more severe form of PMS characterized by increased symptom severity that peaks during the luteal phase and tends to improve or resolve shortly after...